Used in targeted cancer therapy, particularly in clinical research for tumors overexpressing IGF-1R, such as certain types of breast, lung, and colorectal cancers. It works by blocking the insulin-like growth factor 1 receptor (IGF-1R), inhibiting downstream signaling pathways that promote tumor cell proliferation, survival, and metastasis. Dalotuzumab has been investigated in combination with other agents like mTOR inhibitors or chemotherapy to enhance antitumor efficacy, especially in insulin-resistant or hyperinsulinemia-associated cancers. Its development has focused on precision oncology, aiming to exploit IGF pathway dependencies in specific tumor subtypes.